Chris Garabedian, CEO of Sarepta Therapeutics recently sat down with Rare Disease Report to discuss Sarepta's pipeline and more specifically, the company's collaborations with various Duchenne advocacy groups and how important it is that regulatory agencies understand the orphan drug application process from the patient's perspective.
For more information about Sarepta Therapeutics, visit www.sareptatherapeutics.com/

свернуть